Homozygous Familial Hypercholesterolemia Market Report 2026

The homozygous familial hypercholesterolemia market size has grown strongly in recent years. It will grow from $0.37 billion in 2025 to $0.4 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved awareness of rare lipid disorders, expansion of specialty lipid clinics, availability of advanced lipid-lowering drugs, growth in cardiovascular risk screening, improved diagnostic capabilities for genetic diseases.

The homozygous familial hypercholesterolemia market size is expected to see strong growth in the next few years. It will grow to $0.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing adoption of gene and rna-based therapies, rising focus on early pediatric intervention, expansion of reimbursement coverage for rare diseases, growing investment in personalized cardiovascular medicine, increasing clinical trials for novel therapies. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, rising use of pcsk9 inhibitors in treatment regimens, growing integration of personalized lipid management plans, expansion of advanced lipoprotein apheresis services, enhanced focus on long-term patient monitoring.

The increasing disease awareness and early diagnosis are expected to drive the growth of the homozygous familial hypercholesterolemia market going forward. Disease awareness and early diagnosis involve educating healthcare providers, policymakers, and the public about inherited extremely high cholesterol disorders and enhancing identification of affected individuals through systematic screening and testing initiatives. The growth in disease awareness and early diagnosis is fueled by global advocacy efforts promoting universal cholesterol screening, pediatric testing, and cascade screening programs to detect undiagnosed patients sooner. The homozygous familial hypercholesterolemia market facilitates early detection by providing access to advanced diagnostic technologies, specialized lipid clinics, and targeted therapies that strengthen timely identification and long-term disease management. For instance, in March 2025, according to the Korean Hospital Association, a South Korea-based national healthcare organization, the cancer screening rate in 2024 reached 70.2%, representing an increase of approximately 3.8% compared with 2023. Therefore, the increasing disease awareness and early diagnosis is driving the growth of the homozygous familial hypercholesterolemia market.

Companies operating in the homozygous familial hypercholesterolemia market are increasingly focusing on the development of innovative biologic therapies, such as ANGPTL3-targeted monoclonal antibodies, to address the unmet needs of patients with this ultra-rare and severe genetic lipid disorder. ANGPTL3-targeted monoclonal antibody therapies refer to biologic drugs designed to inhibit angiopoietin-like 3, a key regulator of lipid metabolism that suppresses enzymes responsible for lipid breakdown. By blocking ANGPTL3, these therapies reduce LDL-C levels through mechanisms independent of LDL receptor function, which is often defective in homozygous familial hypercholesterolemia patients. For example, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received an expanded approval from the U.S. Food and Drug Administration for Evkeeza (evinacumab-dgnb) for the treatment of children aged 5 to 11 years with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies. Evkeeza is a fully human monoclonal antibody that inhibits ANGPTL3, enabling significant reductions in LDL-C levels in patients who typically show inadequate response to standard treatments. Clinical studies demonstrated an average LDL-C reduction of nearly 48% at 24 weeks in pediatric patients, highlighting the growing role of innovative monoclonal antibody therapies in driving the growth of the homozygous familial hypercholesterolemia market.

In April 2023, Chiesi Farmaceutici S.p.A., an Italy-based biopharmaceutical and healthcare company, acquired Amryt Pharma Plc for an undisclosed amount. Through this acquisition, Chiesi seeks to expand its rare disease portfolio, enhance patient access to innovative treatments, and strengthen its capabilities in developing and commercializing therapies for underserved rare disorders. Amryt Pharma Plc is an Ireland-based commercial-stage biopharmaceutical company specializing in acquiring, developing, and commercializing innovative treatments for rare and orphan diseases, including therapies for genetically driven conditions such as homozygous familial hypercholesterolemia.

Major companies operating in the homozygous familial hypercholesterolemia market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, Amgen, Teva Pharmaceutical Ltd., Viatris Inc., Regeneron Pharmaceuticals Inc., Organon & Co., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca Ionis Pharmaceuticals, CRISPR Therapeutics AG, Arrowhead Pharmaceuticals, Akcea Therapeutics, Esperion Therapeutics, Accord Healthcare, Verve Therapeutics Inc., Aegerion Pharmaceuticals, LIB Therapeutics Inc., and Changzhou Pharmaceutical Factory Co. Ltd.

Tariffs are influencing the homozygous familial hypercholesterolemia market by increasing costs of imported biologic drugs, genetic testing kits, infusion systems, and diagnostic reagents used in long-term disease management. Specialty lipid clinics and hospitals in North America and Europe are most affected due to dependence on imported biologics and diagnostics, while Asia-Pacific faces higher costs for advanced therapies. These tariffs are increasing treatment expenses and affecting access to novel therapies. At the same time, they are encouraging regional manufacturing of biologics, local diagnostic kit production, and expanded domestic research into rare disease treatments.

The homozygous familial hypercholesterolemia market research report is one of a series of new reports that provides homozygous familial hypercholesterolemia market statistics, including homozygous familial hypercholesterolemia industry global market size, regional shares, competitors with a homozygous familial hypercholesterolemia market share, detailed homozygous familial hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the homozygous familial hypercholesterolemia industry. This homozygous familial hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Homozygous familial hypercholesterolemia refers to a rare genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) from birth, leading to premature atherosclerosis and increased risk of cardiovascular events. The condition results from mutations in both alleles of genes responsible for LDL receptor function, severely impairing the body’s ability to remove LDL cholesterol from the blood.

The core types of homozygous familial hypercholesterolemia treatments include statins, proprotein convertase subtilisin/kexin type 9 inhibitors, lomitapide, gene therapy, and RNA-based therapeutics. Statins are drugs that lower cholesterol by inhibiting HMG-CoA reductase, helping manage severe hypercholesterolemia. Treatments are delivered through pharmacologic and small molecule therapies, biologics and monoclonal antibody therapies, advanced lipoprotein apheresis procedures, and investigational gene and RNAI-based therapies. Routes of administration include oral, subcutaneous, and intravenous. Patient age groups include pediatric and adult, and end users comprise specialty lipid clinics, academic hospitals, general hospitals, and payers or managed care organizations.

The homozygous familial hypercholesterolemia market consists of revenues earned by entities by providing services such as genetic testing and diagnostic assessments, lipid profiling and cardiovascular risk evaluation, clinical consultations and personalized treatment planning, apheresis therapy administration, patient monitoring and follow-up, and counseling on lifestyle modifications and disease management. The market value includes the value of related goods sold by the service provider or included within the service offering. The homozygous familial hypercholesterolemia market also includes sales of diagnostic kits for genetic and lipid testing, laboratory reagents, infusion systems for biologic therapies, patient monitoring devices, and adjunctive supplements or nutraceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.